Semaglutide and Autoimmune Conditions: A Complex Interplay

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Semaglutide's anti-inflammatory effects and weight loss can benefit some autoimmune conditions like rheumatoid arthritis. However, emerging research suggests a potential increased risk for certain autoimmune diseases. A thorough discussion with specialists is crucial to weigh benefits against risks and ensure integrated care.

Patients with autoimmune conditions often inquire about the potential impact of semaglutide on their disease activity, especially given its profound effects on metabolism and inflammation. The clinical reality is complex, with emerging research suggesting both potential benefits, particularly through its anti-inflammatory actions and weight loss, and some reported associations with increased risk for certain autoimmune diseases.

Autoimmune diseases are characterized by chronic inflammation where the immune system mistakenly attacks the body"s own tissues. Obesity and metabolic dysfunction are increasingly recognized as exacerbating factors for many autoimmune conditions, contributing to a heightened inflammatory state. Semaglutide, as a GLP-1 receptor agonist, possesses significant anti-inflammatory properties. It reduces systemic inflammation and oxidative stress, which are key drivers of autoimmune pathology. RheumatologistOnCall (2025) notes that GLP-1 helps reduce this inflammatory burden, which is why people with autoimmune diseases often feel better when they lose even 5–10% of body weight. This suggests that semaglutide"s ability to improve metabolic health and reduce inflammation could theoretically lead to a decrease in autoimmune disease activity.

The most compelling evidence for benefit lies in inflammatory conditions where obesity is a significant comorbidity, such as rheumatoid arthritis (RA) and psoriatic arthritis. Weight loss achieved with semaglutide can directly reduce the mechanical stress on joints and decrease the production of pro-inflammatory adipokines from adipose tissue. Beyond weight loss, GLP-1 receptor agonists have been shown to modulate immune cell function and cytokine production. Research presented at ACR Convergence (2025) highlighted the potential of GLP-1 therapies in rheumatic disease management. Specifically, a study found that RA patients prescribed semaglutide had lower risks of RA flare-ups, including synovitis, stiffness, swelling, and joint pain, compared to those not on the medication (ACR Abstracts, 2025). Furthermore, GLP-1RAs have been linked to reduced RA disease activity and improved cardiovascular risk profiles in patients with overweight or obesity (Rheumatology Advisor, 2025). This suggests a direct therapeutic effect beyond just weight reduction.

However, the picture is not uniformly positive. Some recent studies have raised concerns about a potential association between GLP-1 receptor agonists and an increased risk of certain autoimmune diseases. Lee et al. (2025) conducted a study suggesting that GLP-1 RAs were linked to elevated risks of rheumatoid arthritis, autoimmune thyroiditis, ankylosing spondylitis, and psoriasis in both males and females. This finding, also reported in PubMed (2025), indicates that compared with DPP-4 inhibitors, the use of GLP-1 RAs might be associated with increased risks of specific autoimmune conditions. This discrepancy highlights the complexity of immune system modulation and the need for further research to understand these associations fully. Unlike the clear benefits seen in metabolic health, the interaction with the broader immune system in autoimmune contexts requires careful consideration.

Clinical nuance is paramount when considering semaglutide for patients with autoimmune conditions. The decision to use semaglutide should involve a thorough discussion with your rheumatologist or immunologist, weighing the potential benefits of weight loss and anti-inflammatory effects against any reported risks or individual disease activity. For some, the metabolic improvements and reduction in inflammation may significantly improve their overall health and quality of life, potentially leading to better control of their autoimmune disease. For others, particularly those with specific autoimmune profiles or a history of certain conditions, the risks might outweigh the benefits. This is not a one-size-fits-all scenario.

For patients with autoimmune conditions on semaglutide, the practical takeaway is to maintain open and continuous communication with your entire healthcare team. Report any new or worsening symptoms of your autoimmune disease promptly. Ensure regular monitoring of inflammatory markers and disease activity. Unlike making assumptions, a collaborative approach between your endocrinologist (or prescribing physician) and your rheumatologist/immunologist is essential to tailor treatment plans that optimize both metabolic and autoimmune health. This integrated care model ensures that you receive personalized advice and that any potential interactions or side effects are managed effectively, leading to the best possible outcomes for your complex health needs.